Skip to main content

Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect



CAS Number: 1211441-98-3

Therapeutic Category
Anti-Cancer/ Oncology
API Technology
Dose Form
Oral Solid/Tablets
Dr Reddy's Development Status
Innovator Brand (USA)

Mechanism of Action

Ribociclib is a cancer medication that works by inhibiting the activity of specific enzymes called cyclin-dependent kinases (CDKs) 4 and 6. These enzymes play a critical role in the regulation of cell division, and their overactivity is commonly associated with the development of certain types of cancer, particularly breast cancer.

By blocking the activity of CDK4/6, ribociclib slows down the uncontrolled cell division that drives the growth of cancer cells. This helps to reduce the size of tumors and slows down the progression of the disease.

Ribociclib is typically used in combination with other cancer treatments, such as hormone therapy, to help improve the overall effectiveness of treatment. The drug is approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor.


Ribociclib is a medication used for the treatment of certain types of breast cancer. It is specifically indicated for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor.

This type of breast cancer is characterized by the presence of certain hormones (estrogen and/or progesterone) that help to fuel the growth of the cancer cells. Ribociclib is used to target these hormones and slow down the progression of the disease.

In clinical trials, ribociclib has been shown to significantly improve progression-free survival (the length of time during which a patient's cancer does not worsen) compared to treatment with an aromatase inhibitor alone. This makes it an important option for women with advanced or metastatic breast cancer who are seeking to extend the time until their cancer progresses.

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Ribociclib API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Ribociclib API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.

Oncology API Products:

Learn More

Contact Us

Please fill in the following form for API Requirement & we'll get back to you shortly

We are here to help, if you have any country specific requirements.


No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.